Become a Client
JPMorgan Funds - Global Healthcare Fund A (acc) - EUR
JPMorgan Funds (SICAV domiciled in Luxembourg)
Key Information
Legal Documents

Fund Profile

Category: SICAV

To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. INVESTMENT PROCESS Investment approach B Uses a research-driven investment process that is based on the fundamental analysis of companies and their future earnings and cash flows by a team of specialist sector analysts. B Targets attractively valued companies using strong scientific rationale as the basis for all investment decisions. Share Class Benchmark MSCI World Healthcare Index (Total Return Net) Benchmark uses and resemblance B Performance comparison. The Sub-Fund is actively managed. Though the majority of its holdings (excluding derivatives) are likely to be components of the benchmark, the Investment Manager has broad discretion to deviate from its securities, weightings and risk characteristics. The degree to which the Sub-Fund may resemble the composition and risk characteristics of the benchmark will vary over time and its performance may be meaningfully different. POLICIES Main investment exposure At least 67% of assets invested in Healthcare Companies anywhere in the world. The Sub-Fund may invest in smaller capitalisation companies. At least 51% of assets are invested in companies with positive environmental and/or social characteristics that follow good governance practices as measured through the Investment Manager's proprietary ESG scoring methodology and/or third party data. The Investment Manager evaluates and applies values and norms based screening to implement exclusions. To support this screening, it relies on third party provider(s) who identify an issuer’s participation in or the revenue which they derive from activities that are inconsistent with the values and norms based screens. The list of screens applied that may result in exclusions can be found on the Management Company’s Website (www. The Sub-Fund systematically includes ESG analysis in its investment decisions on at least 90% of securities purchased. Derivatives Used for: efficient portfolio management; hedging. Types: see Sub-Fund Derivatives Usage table under How the Sub-Funds Use Derivatives, Instruments and Techniques in the Prospectus. TRS including CFD: none. Global exposure calculation method: commitment. Currencies Sub-Fund Base Currency: USD. Currencies of asset denomination: any. Hedging approach: typically managed to the currency weights of the benchmark. Redemption and Dealing Shares of the Sub-Fund may be redeemed on demand, with dealing normally on a daily basis. Distribution Policy This Share Class does not pay dividends. Earned income is retained in the NAV. For an explanation of some of the terms used in this document, please visit the glossary on our website at

Morningstar Rating
More information about the calculation of the Morningstar Ratings
Risk and reward profile
Lower Risk
Possible Lower
Higher Risk
Possible Higher
Key Information
Closing Price 18/10/2021259.41
Morningstar categorySector Equity Healthcare
Distribution statusAccumulating
Inception Date01/02/2013
Minimum initial amount500.00 EUR
Fees And Charges
Entry feeNone
Custody feeNone
Exit feeNone
Ongoing charge1.73% of which none is paid to MeDirect
Fund management company
AddressJPMorgan Asset Management (Europe) S.à r.l. European Bank & Business Centre 6, route de Trèves Luxembourg L-2633 Luxembourg
Manager NameAnne Marden
Manager Start Date02/10/2009
Total Net Assets (mil)4,322.08 EUR (30/09/2021)
AdministratorJPMorgan Asset Management (Europe) S.à r.l.


en 30/07/2021
Annual Report
en 30/06/2020
Semi Annual Report
en 31/12/2020
Morningstar Report


Historical returns are no guarantee for future performances. Investing in Financial markets and securities involves risk. Past performance is not a guarantee of future results. Investment losses may occur and investors could lose some or all of their investment in the Fund.
Entry fees, purchase charges, custody fees, exit fees, sale charges and taxes are not included in the calculation of past performance. Ongoing charges (including management fees, administrative fees and other costs) have been taken in to account, as they are already included in the price/NAV of the fund.
Annualised performance in EUR
PeriodAnnualised returnDate
1 year15.49%15/10/2021
3 years14.42%15/10/2021
5 years12.69%15/10/2021
Since launch15.73%15/10/2021
Cumulative performance in EUR
YTD 01/01/202112.89
1 month0.46
3 months1.64
6 months7.67
Quarterly Returns
Q 1Q 2Q 3Q 4


Asset Allocation
% Long% Short% Net Assets
Return/Risk Analysis
Risk Measurement1 Year3 Years5 Years
Standard Deviation
Sharpe Ratio
Sortino Ratio
Positive Months9.0024.0037.00
Negative Months3.0012.0023.00
Worst Month-4.30-9.99-9.99
World Regions
United States73.71
Europe - ex Euro14.01
United Kingdom3.90
Latin America1.03
Asia - Developed0.49
Asia - Emerging0.11
Stock Sector Weighting
Sector% of Equity
Basic Materials0.30
Top 10 Holdings
HoldingSectorCountry% of Assets
UnitedHealth Group Inc HealthcareUnited States6.78
Thermo Fisher Scientific Inc HealthcareUnited States4.71
Roche Holding AG HealthcareSwitzerland4.32
AstraZeneca PLC HealthcareUnited Kingdom3.66
Eli Lilly and Co HealthcareUnited States3.32
Bristol-Myers Squibb Co HealthcareUnited States3.20
Novo Nordisk A/S Class B HealthcareDenmark3.19
Johnson & Johnson HealthcareUnited States3.13
Novartis AG HealthcareSwitzerland2.63
Intuitive Surgical Inc HealthcareUnited States2.53
Classification of Morningstar Category
Ranking1 Year2 Years3 Years5 Years
Top 25%
Category above the average
Category below the average
Bottom 25%
Morningstar Style Box
Equity Style
Closing Price
All key information and documents must be reviewed before being able to Invest.

© 2021 MeDirect Bank (Malta) plc. All rights reserved.
MeDirect Bank (Malta) plc, company registration number C34125, is licensed to undertake the business of banking in terms of the Banking Act (Cap. 371) and investment services under the Investment Services Act (Cap. 370). MeDirect Bank (Malta) plc is regulated by the Malta Financial Services Authority as a Credit Institution under the Banking Act 1994.